Imatinib Unknown Status Phase 1 Trials for Chordomas Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01175109Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma